Compare CCCC & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | ELA |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 325.1M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | ELA |
|---|---|---|
| Price | $2.50 | $12.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $8.50 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.4M | 65.4K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.79 |
| EPS | N/A | ★ 0.39 |
| Revenue | $30,108,000.00 | ★ $208,843,961.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | $2.46 |
| P/E Ratio | ★ N/A | $32.12 |
| Revenue Growth | N/A | ★ 23.18 |
| 52 Week Low | $1.09 | $5.10 |
| 52 Week High | $4.70 | $13.73 |
| Indicator | CCCC | ELA |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 68.41 |
| Support Level | $2.50 | $11.96 |
| Resistance Level | $2.69 | $12.86 |
| Average True Range (ATR) | 0.18 | 0.71 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 23.86 | 67.70 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.